Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E K Rowinsky

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1994
Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumorsE K Rowinsky, D A Noe, D L Trump, et al.
Blood|March 21, 1998
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyureaG I Rodriguez, J G Kuhn, G R Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1991
Sequences of taxol and cisplatin: a phase I and pharmacologic studyE K Rowinsky, M R Gilbert, W P McGuire, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignanciesC D Britten, E K Rowinsky, S Soignet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2001
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory propertiesA W Tolcher, S G Eckhardt, J Kuhn, et al.
Cancer Research|August 1, 1990
Phase I and pharmacokinetic study of brequinar sodium (NSC 368390)D A Noe, E K Rowinsky, H S Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignanciesE K Rowinsky, R Humphrey, L A Hammond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 4, 2001
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patientsM A Villalona-Calero, J L Blum, S E Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1992
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitorE K Rowinsky, L B Grochow, C B Hendricks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenaseS D Baker, S P Khor, A A Adjei, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1994
Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumorsE K Rowinsky, D A Noe, D L Trump, et al.
Blood|March 21, 1998
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyureaG I Rodriguez, J G Kuhn, G R Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1991
Sequences of taxol and cisplatin: a phase I and pharmacologic studyE K Rowinsky, M R Gilbert, W P McGuire, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignanciesC D Britten, E K Rowinsky, S Soignet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2001
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory propertiesA W Tolcher, S G Eckhardt, J Kuhn, et al.
Cancer Research|August 1, 1990
Phase I and pharmacokinetic study of brequinar sodium (NSC 368390)D A Noe, E K Rowinsky, H S Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignanciesE K Rowinsky, R Humphrey, L A Hammond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 4, 2001
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patientsM A Villalona-Calero, J L Blum, S E Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1992
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitorE K Rowinsky, L B Grochow, C B Hendricks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenaseS D Baker, S P Khor, A A Adjei, et al.
Pageof 16